Survival outcomes in breast cancer patients with low estrogen/progesterone receptor expression

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Introduction The prognostic value of low estrogen and progesterone receptors expression (ER/PgR 1%-10%) in early breast cancer patients is still unclear. Patients and Methods We retrospectively analyzed 1424 consecutive patients with HER2/neu-negative and low endocrine receptors expression early breast cancer, submitted to surgery at the European Institute of Oncology between January 1995 and December 2009. Patients were classified according to the percentage of ER/PgR expression using immunohistochemistry. Group 1 with ER/PgR <1%, and group 2 with ER/PgR 1% to 10%. Results Group 1 (ER/PgR <1%) included 1300 patients, and group 2 (ER/PgR 1%-10%) 124 patients. Median follow-up time was 74 months (range, 3-192 months). The 5-year disease-free survival (DFS) rate was 74% (95% confidence interval [CI], 72%-77%) for group 1, and 79% (95% CI, 70%-86%) for group 2 (P =.16). The 5-year overall survival (OS) rate was 86% (95% CI, 84%-88%) in group 1 and 90% (95% CI, 83%-95%) in group 2 (P =.13). In patients without lymph node involvement, the 5-year OS rate was 92% (95% CI, 89.5%-93.6%) for group 1 and 98% (95% CI, 90.2%-99.8%) for group 2 (P =.061). One hundred ten patients received endocrine therapy with no significant effect on DFS (P =.36) and OS (P =.30). Conclusion The ER/PgR 1%-10% group had a slight, but not statistically significant, better prognosis than the ER/PgR

Original languageEnglish
Pages (from-to)258-264
Number of pages7
JournalClinical Breast Cancer
Volume14
Issue number4
DOIs
Publication statusPublished - 2014

Fingerprint

Progesterone Receptors
Estrogen Receptors
Breast Neoplasms
Survival
Confidence Intervals
Survival Rate
Disease-Free Survival
Lymph Nodes
Immunohistochemistry

Keywords

  • Adjuvant treatment
  • Estrogen receptor
  • Histologic subtypes
  • Low endocrine responsiveness
  • Overall survival

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)

Cite this

@article{4c1f7a63ac8a4bcebf125c4138f419b7,
title = "Survival outcomes in breast cancer patients with low estrogen/progesterone receptor expression",
abstract = "Introduction The prognostic value of low estrogen and progesterone receptors expression (ER/PgR 1{\%}-10{\%}) in early breast cancer patients is still unclear. Patients and Methods We retrospectively analyzed 1424 consecutive patients with HER2/neu-negative and low endocrine receptors expression early breast cancer, submitted to surgery at the European Institute of Oncology between January 1995 and December 2009. Patients were classified according to the percentage of ER/PgR expression using immunohistochemistry. Group 1 with ER/PgR <1{\%}, and group 2 with ER/PgR 1{\%} to 10{\%}. Results Group 1 (ER/PgR <1{\%}) included 1300 patients, and group 2 (ER/PgR 1{\%}-10{\%}) 124 patients. Median follow-up time was 74 months (range, 3-192 months). The 5-year disease-free survival (DFS) rate was 74{\%} (95{\%} confidence interval [CI], 72{\%}-77{\%}) for group 1, and 79{\%} (95{\%} CI, 70{\%}-86{\%}) for group 2 (P =.16). The 5-year overall survival (OS) rate was 86{\%} (95{\%} CI, 84{\%}-88{\%}) in group 1 and 90{\%} (95{\%} CI, 83{\%}-95{\%}) in group 2 (P =.13). In patients without lymph node involvement, the 5-year OS rate was 92{\%} (95{\%} CI, 89.5{\%}-93.6{\%}) for group 1 and 98{\%} (95{\%} CI, 90.2{\%}-99.8{\%}) for group 2 (P =.061). One hundred ten patients received endocrine therapy with no significant effect on DFS (P =.36) and OS (P =.30). Conclusion The ER/PgR 1{\%}-10{\%} group had a slight, but not statistically significant, better prognosis than the ER/PgR",
keywords = "Adjuvant treatment, Estrogen receptor, Histologic subtypes, Low endocrine responsiveness, Overall survival",
author = "Alessandra Balduzzi and Vincenzo Bagnardi and Nicole Rotmensz and Silvia Dellapasqua and Emilia Montagna and Anna Cardillo and Giuseppe Viale and Paolo Veronesi and Mattia Intra and Alberto Luini and Giancarlo Pruneri and Giuseppe Mastropasqua and Aron Goldhirsch and Marco Colleoni",
year = "2014",
doi = "10.1016/j.clbc.2013.10.019",
language = "English",
volume = "14",
pages = "258--264",
journal = "Clinical Breast Cancer",
issn = "1526-8209",
publisher = "Elsevier",
number = "4",

}

TY - JOUR

T1 - Survival outcomes in breast cancer patients with low estrogen/progesterone receptor expression

AU - Balduzzi, Alessandra

AU - Bagnardi, Vincenzo

AU - Rotmensz, Nicole

AU - Dellapasqua, Silvia

AU - Montagna, Emilia

AU - Cardillo, Anna

AU - Viale, Giuseppe

AU - Veronesi, Paolo

AU - Intra, Mattia

AU - Luini, Alberto

AU - Pruneri, Giancarlo

AU - Mastropasqua, Giuseppe

AU - Goldhirsch, Aron

AU - Colleoni, Marco

PY - 2014

Y1 - 2014

N2 - Introduction The prognostic value of low estrogen and progesterone receptors expression (ER/PgR 1%-10%) in early breast cancer patients is still unclear. Patients and Methods We retrospectively analyzed 1424 consecutive patients with HER2/neu-negative and low endocrine receptors expression early breast cancer, submitted to surgery at the European Institute of Oncology between January 1995 and December 2009. Patients were classified according to the percentage of ER/PgR expression using immunohistochemistry. Group 1 with ER/PgR <1%, and group 2 with ER/PgR 1% to 10%. Results Group 1 (ER/PgR <1%) included 1300 patients, and group 2 (ER/PgR 1%-10%) 124 patients. Median follow-up time was 74 months (range, 3-192 months). The 5-year disease-free survival (DFS) rate was 74% (95% confidence interval [CI], 72%-77%) for group 1, and 79% (95% CI, 70%-86%) for group 2 (P =.16). The 5-year overall survival (OS) rate was 86% (95% CI, 84%-88%) in group 1 and 90% (95% CI, 83%-95%) in group 2 (P =.13). In patients without lymph node involvement, the 5-year OS rate was 92% (95% CI, 89.5%-93.6%) for group 1 and 98% (95% CI, 90.2%-99.8%) for group 2 (P =.061). One hundred ten patients received endocrine therapy with no significant effect on DFS (P =.36) and OS (P =.30). Conclusion The ER/PgR 1%-10% group had a slight, but not statistically significant, better prognosis than the ER/PgR

AB - Introduction The prognostic value of low estrogen and progesterone receptors expression (ER/PgR 1%-10%) in early breast cancer patients is still unclear. Patients and Methods We retrospectively analyzed 1424 consecutive patients with HER2/neu-negative and low endocrine receptors expression early breast cancer, submitted to surgery at the European Institute of Oncology between January 1995 and December 2009. Patients were classified according to the percentage of ER/PgR expression using immunohistochemistry. Group 1 with ER/PgR <1%, and group 2 with ER/PgR 1% to 10%. Results Group 1 (ER/PgR <1%) included 1300 patients, and group 2 (ER/PgR 1%-10%) 124 patients. Median follow-up time was 74 months (range, 3-192 months). The 5-year disease-free survival (DFS) rate was 74% (95% confidence interval [CI], 72%-77%) for group 1, and 79% (95% CI, 70%-86%) for group 2 (P =.16). The 5-year overall survival (OS) rate was 86% (95% CI, 84%-88%) in group 1 and 90% (95% CI, 83%-95%) in group 2 (P =.13). In patients without lymph node involvement, the 5-year OS rate was 92% (95% CI, 89.5%-93.6%) for group 1 and 98% (95% CI, 90.2%-99.8%) for group 2 (P =.061). One hundred ten patients received endocrine therapy with no significant effect on DFS (P =.36) and OS (P =.30). Conclusion The ER/PgR 1%-10% group had a slight, but not statistically significant, better prognosis than the ER/PgR

KW - Adjuvant treatment

KW - Estrogen receptor

KW - Histologic subtypes

KW - Low endocrine responsiveness

KW - Overall survival

UR - http://www.scopus.com/inward/record.url?scp=84904617944&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84904617944&partnerID=8YFLogxK

U2 - 10.1016/j.clbc.2013.10.019

DO - 10.1016/j.clbc.2013.10.019

M3 - Article

VL - 14

SP - 258

EP - 264

JO - Clinical Breast Cancer

JF - Clinical Breast Cancer

SN - 1526-8209

IS - 4

ER -